The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Chris Brookes-Smith could have died from eating peanuts - but taking part in a clinical trial has changed his life.

ADULTS can beat peanut allergies by eating tiny amounts with medical help and building up a tolerance, an NHS study suggests.

The FDA has approved Dupixent for the treatment of patients aged 12 years and older with CSU who remain symptomatic despite H1 antihistamine treatment.

Living with Chronic Spontaneous Urticaria can be challenging, especially when triggers seem ubiquitous. Here's what you need ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.

Who Is This Treatment For? Chronic spontaneous urticaria, aka CSU, happens when a person develops itchy hives that persist ... was originally developed to treat adults and children 12 years ...

The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) to treat adults and ...